

ASX Announcement

10 October 2022

emyria

myriad data.
individual care.

Emyria Investor Webinar - October 13

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech informed by patient experience and tackling unmet needs in neuroscience & mental health, is pleased to invite shareholders to an overview of its novel, MDMA-inspired Drug Discovery Program and world-leading partnership with The University of Western Australia (UWA) to be held on: **Thursday 13 October at 11:00 am AEDT.**

emyria		THURSDAY 13 OCT	REGISTER TODAY
MDMA WEBINAR	EMYRIA CEO & MD DR MICHAEL WINLO	UWA ASSOCIATE PROFESSOR DR MATT PIGGOTT	

Emyria's Managing Director Dr Michael Winlo & UWA Associate Professor Dr Matt Piggott will present an update into the developments of their joint MDMA-inspired drug discovery program aimed at developing MDMA-like analogues with the potential to treat psychological disorders, including the recently announced collaboration with PsychoGenics. The presentation deck will be available to the ASX platform the morning of the webinar.

EVENT DETAILS: "MDMA-INSPIRED DRUG DISCOVERY"

WEBINAR PRESENTERS Emyria's Managing Director, Dr Michael Winlo and UWA Associate Professor, Dr Matthew Piggott

DATE Thursday 13 October

TIME 11:00am Sydney time (AEDT)

WHERE Webinar - details to be provided upon registration

TO REGISTER, please click on the link: https://janemorganmanagement-au.zoom.us/webinar/register/WN_eApCFQsHQOKram4T6gmt5Q

After registering your interest, you will receive a confirmation email with information about joining the webinar.

Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to Lexi O'Halloran at: lexi@janemorganmanagement.com.au

emyria

ABOUT EMYRIA | emyria.com

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes via:

- **Drug Development:** Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria's first dose form, EMD-RX5 is in Phase 3 trials
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

EMYRIA'S INTERACTIVE INVESTOR HUB investorhub.emyria.com

Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

This announcement has been approved and authorised for release by the Board of Emyria Limited.

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.